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Lithium for long-term treatment of 
unipolar depression 
 
Lithium is the third element in the periodic table, and although lithium is present in the natural 
environment and is used to make batteries, it is perhaps best known as a therapeutic drug. Lithium 
in various forms was used to treat neuropsychiatric disorders before falling into disuse because of 
concerns over toxicity. The Australian psychiatrist John Cade rediscovered lithium  for  the treatment 
of mania in 1949 and the Danish psychiatrist Mogens Schou did one of the first randomised 
controlled trials in mania in 1954  assessing lithium use, also suggesting the potential for use of 
lithium as a prophylactic  drug for depressive illness. The use of lithium was opposed in the 1960s by 
some researchers from the Maudsley Hospital,1 although evidence from later clinical trials did not 
support this position. Lithium is now accepted as a treatment for bipolar disorder in evidence-based 
guidelines, and systematic reviews show the adverse effects to be acceptable, albeit with a 
continuing concern about the effects of long-term use on renal function.2 Despite the increasing 
evidence of benefits, lithium seems to be being used less. Other benefits of lithium treatment have 
been described, including a reduction of mortality and suicide by more than 60% in people with 
major depression or bipolar disorder,3 a putative preventative effect for dementia,4 and, perhaps 
most notably, a report published in 2016 showed that lithium is associated with a reduced overall 
cancer risk in patients with bipolar disorder, and a dose– response relationship for  cancer risk 
reduction was observed.5 
Evidence from early meta-analyses supported Schou’s suggestion of the use of lithium for 
depression. Indeed, Souza and Goodwin6   stated in 1991 that “There is no reason to doubt the 
efficacy of lithium in the prophylaxis of unipolar depressive illness”. Recent treatment guidelines 
from 2017 also acknowledge the role of lithium in treating unipolar depressive disorder, although 
the emphasis for both acute and continuation phase  treatment   is  on  lithium  as  an  augmenting 
drug (i.e., an adjunct).7 The paper by Jari Tiihonen and colleagues is a most helpful addition to the 
available literature; they  studied  the  risk of  readmission to hospital between  1996  and  2012 in 
all patients  in Finland (n=123 712; mean follow-up time 7·9 years) who had been admitted to 
hospital for unipolar depression, using nationwide databases for hospital admissions, mortality, and 
dispensed medications. These data show that lithium use was associated with a markedly lower risk 
of readmission to hospital compared with no use, whereas antidepressants and antipsychotics were 
not associated with any such benefits. Particularly important was the finding that risk of readmission 
to hospital was lower during sole lithium therapy than during its concomitant use with 
antidepressants. The only other drug treatments approaching the effectiveness of lithium were 
clozapine and amitriptyline. When analyses controlling for various biases were done, all drugs 
performed somewhat better; however, the same rank order in comparative effectiveness as the 
primary analysis was preserved. Although clearly  not  derived from a randomised design, these 
findings also broadly agree with a recent Cochrane meta-analysis of relevant trials and thus reconcile 
randomised and population- based data.8    Tiihonen and  colleagues conclude that “lithium, 
especially without concomitant antidepressant use, is the pharmacological treatment  associated 
with the  lowest risk of  hospital readmission for  mental illness in  patients  with  severe unipolar 
depression”. Notably, outcomes associated with the most widely used treatments (antidepressants, 
aripiprazole, and quetiapine) are modest compared with outcomes associated with lithium. 
Replication of these findings is needed, and should be possible given that similar databases exist in 
other countries (eg, Denmark and Taiwan). These data could be easily assessed to establish whether 
they replicate the Finnish findings or not. The findings of Tiihonen and colleagues are particularly 
noteworthy because of recent disquiet about the use of antidepressants in unipolar mood 
disorders,9 and they suggest that lithium monotherapy might be the best long-term prophylactic 
drug. 
The findings of Tiihonen and colleagues might also reawaken research interest in lithium, which has 
waned in recent decades. Lithium is not simply a medicine, but an element present in the natural 
environment and in both food and drinking water to varying degrees. Of the many potential effects 
of environmental lithium on brain and behaviour, a reduction in suicide prevalence at a population 
level is the most consistently found, an effect that appears to  be independent of lithium 
prescriptions.10 The findings of Tiihonen and colleagues from their Finnish National data should be 
replicated; more  randomised trials of  lithium monotherapy  in unipolar depression should be 
conducted and, if the benefits are verified, practice should reflect this. Finally, all aspects of lithium 
and its effects on the brain and behaviour should be the focus of continuing rigorous scientific 
enquiry. 
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